Effective and new potent drug combination: Histone deacetylase and wnt/beta-catenin pathway inhibitors in lung carcinoma cells
dc.contributor.author | Erkisa, Merve | |
dc.contributor.buuauthor | Akgün, Oğuzhan | |
dc.contributor.buuauthor | Arı, Ferda | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji, Moleküler Biyoloji Bölümü. | tr_TR |
dc.contributor.orcid | 0000-0002-8410-1786 | tr_TR |
dc.contributor.orcid | 0000-0002-6729-7908 | tr_TR |
dc.contributor.researcherid | A-5608-2019 | tr_TR |
dc.contributor.researcherid | AAG-7012-2021 | tr_TR |
dc.contributor.scopusid | 57194269996 | tr_TR |
dc.contributor.scopusid | 24376085300 | tr_TR |
dc.date.accessioned | 2024-02-09T07:31:37Z | |
dc.date.available | 2024-02-09T07:31:37Z | |
dc.date.issued | 2019-09 | |
dc.description.abstract | Lung cancer is the most commonly diagnosed cancer worldwide with a high mortality rate. In this study, the therapeutic effect of combination valproic acid and niclosamide was investigated on human lung cancer cell line. The effects of the compounds alone and combination therapy on cell viability were determined by sulforhodamine B and adenosine 5 '-triphosphate viability assays. Flow cytometry was used to determine the cell death mechanism and DNA damage levels responsible for the cytotoxic effects of combination therapy. The presence of apoptosis in cells was supported by fluorescence microscopy and also by using inhibitors of the apoptotic signaling pathway. The increase in cellular reactive oxygen species (ROS) level in combination therapy was determined by H2DCFDA staining. The effect of N-acetyl-l-cysteine combination on ROS increase was investigated on cell viability. In addition, the expression levels of the proteins associated with epigenetic regulation and cell death were analyzed by Western blotting and gene expression levels were determined using real-time quantitative polymerase chain reaction.It was observed that the combination therapy showed a cytotoxic effect on the A549 lung cancer cells compared to the individual use of the inhibitors. The absence of this effect on normal lung cells revealed the presence of a selective toxic effect. When the mechanism of cytotoxicity is examined, it has been observed that combination therapy initiates the activation of tumor necrosis receptors and causes apoptosis by activated caspase. It was also observed that this extrinsic apoptotic pathway was activated on the mitochondrial pathway. In addition, ER stress and mitochondrial membrane potential loss associated with increased ROS levels induce cell death. When the data in this study were evaluated, combination therapy caused a dramatic decrease in cell viability by inducing the extrinsic apoptotic pathway in lung cancer cell line. Therefore, it was concluded that it can be used as an effective and new treatment option for lung cancer. | en_US |
dc.identifier.citation | Akgün, O. ve Arı, F. (2019). ''Effective and new potent drug combination: Histone deacetylase and wnt/beta-catenin pathway inhibitors in lung carcinoma cells''. Journal of Cellular Biochemistry, 120(9), 15467-15482. | en_US |
dc.identifier.endpage | 15482 | tr_TR |
dc.identifier.issn | 0730-2312 | |
dc.identifier.issn | 1097-4644 | |
dc.identifier.issue | 9 | tr_TR |
dc.identifier.pubmed | 31037769 | tr_TR |
dc.identifier.scopus | 2-s2.0-85069524183 | tr_TR |
dc.identifier.startpage | 15467 | tr_TR |
dc.identifier.uri | https://doi.org/10.1002/jcb.28813 | en_US |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1002/jcb.28813 | en_US |
dc.identifier.uri | https://hdl.handle.net/11452/39606 | en_US |
dc.identifier.volume | 120 | en_US |
dc.identifier.wos | 000476804200119 | |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.bap | OUAP (F)-2015/15 | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Journal of Cellular Biochemistry | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Biochemistry & bolecular biology | en_US |
dc.subject | Cell biology | en_US |
dc.subject | Apoptosis | en_US |
dc.subject | Lung cancer | en_US |
dc.subject | Niclosamide | en_US |
dc.subject | Valproic acid | en_US |
dc.subject | Endoplasmic-reticulum stress | en_US |
dc.subject | Valproic acid | en_US |
dc.subject | Growth-inhibition | en_US |
dc.subject | Targeted Therapy | en_US |
dc.subject | Down-regulation | en_US |
dc.subject | Up-regulation | en_US |
dc.subject | Cancer cells | en_US |
dc.subject | In-vitro | en_US |
dc.subject | Niclosamide | en_US |
dc.subject | Apoptosis | en_US |
dc.subject.emtree | Acetylcysteine | en_US |
dc.subject.emtree | Adenosine triphosphate | en_US |
dc.subject.emtree | Caspase 3 | en_US |
dc.subject.emtree | Caspase 7 | en_US |
dc.subject.emtree | Caspase 8 | en_US |
dc.subject.emtree | Cytokeratin 18 | en_US |
dc.subject.emtree | Histone deacetylase | en_US |
dc.subject.emtree | Histone deacetylase 1 | en_US |
dc.subject.emtree | Histone deacetylase 2 | en_US |
dc.subject.emtree | Histone H3 | en_US |
dc.subject.emtree | Niclosamide | en_US |
dc.subject.emtree | Reactive oxygen metabolite | en_US |
dc.subject.emtree | Valproic acid | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Histone deacetylase inhibitor | en_US |
dc.subject.emtree | Niclosamide | en_US |
dc.subject.emtree | Reactive oxygen metabolite | en_US |
dc.subject.emtree | Valproic acid | en_US |
dc.subject.emtree | A-549 cell line | en_US |
dc.subject.emtree | Antineoplastic activity | en_US |
dc.subject.emtree | Apoptosis | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Bronchial cell line | en_US |
dc.subject.emtree | Cell density | en_US |
dc.subject.emtree | Cell viability | en_US |
dc.subject.emtree | Combination drug therapy | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | DNA damage | en_US |
dc.subject.emtree | Drug cytotoxicity | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug potency | en_US |
dc.subject.emtree | Endoplasmic reticulum stress | en_US |
dc.subject.emtree | Flow cytometry | en_US |
dc.subject.emtree | Fluorescence microscopy | en_US |
dc.subject.emtree | Gene expression level | en_US |
dc.subject.emtree | Histone acetylation | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human cell | en_US |
dc.subject.emtree | Ic50 | en_US |
dc.subject.emtree | Lung carcinoma | en_US |
dc.subject.emtree | Mitochondrial membrane potential | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Wnt signaling | en_US |
dc.subject.emtree | Cell proliferation | en_US |
dc.subject.emtree | Cell survival | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | Drug potentiation | en_US |
dc.subject.emtree | Genetic epigenesis | en_US |
dc.subject.emtree | Genetics | en_US |
dc.subject.emtree | Lung tumor | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Tumor cell line | en_US |
dc.subject.emtree | Wnt signaling | en_US |
dc.subject.mesh | A549 cells | en_US |
dc.subject.mesh | Antineoplastic combined chemotherapy protocols | en_US |
dc.subject.mesh | Cell line, tumor | en_US |
dc.subject.mesh | Cell proliferation | en_US |
dc.subject.mesh | Cell survival | en_US |
dc.subject.mesh | DNA damage | en_US |
dc.subject.mesh | Drug synergism | en_US |
dc.subject.mesh | Epigenesis, genetic | en_US |
dc.subject.mesh | Histone deacetylase inhibitors | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Lung neoplasms | en_US |
dc.subject.mesh | Membrane potential | en_US |
dc.subject.mesh | Mitochondrial | en_US |
dc.subject.mesh | Niclosamide | en_US |
dc.subject.mesh | Reactive oxygen species | en_US |
dc.subject.mesh | Valproic acid | en_US |
dc.subject.mesh | Wnt signaling pathway | en_US |
dc.subject.scopus | Apoptosis; Pyrvinium Embonate; Cestode Infections | en_US |
dc.subject.wos | Biochemistry & molecular biology | en_US |
dc.subject.wos | Cell biology | en_US |
dc.title | Effective and new potent drug combination: Histone deacetylase and wnt/beta-catenin pathway inhibitors in lung carcinoma cells | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q2 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: